OncoSec Medical Incorporated (ONCS) Shares Down 0.4%

OncoSec Medical Incorporated (NASDAQ:ONCS) fell 0.4% during trading on Wednesday . The company traded as low as $2.20 and last traded at $2.36. 5,349,000 shares traded hands during mid-day trading, an increase of 536% from the average session volume of 840,485 shares. The stock had previously closed at $2.35.

A number of research firms have recently commented on ONCS. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price objective on shares of OncoSec Medical in a research note on Thursday, November 9th. ValuEngine raised shares of OncoSec Medical from a “strong sell” rating to a “sell” rating in a research note on Thursday, November 9th. Finally, Maxim Group reaffirmed a “buy” rating and issued a $5.00 price objective on shares of OncoSec Medical in a research note on Thursday, October 26th. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. OncoSec Medical has an average rating of “Buy” and a consensus target price of $5.33.

OncoSec Medical (NASDAQ:ONCS) last issued its earnings results on Wednesday, October 25th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.05). equities analysts forecast that OncoSec Medical Incorporated will post -0.86 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This story was first published by Markets Daily and is owned by of Markets Daily. If you are reading this story on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this story can be viewed at https://www.themarketsdaily.com/2017/11/16/oncosec-medical-incorporated-oncs-shares-down-0-4.html.

About OncoSec Medical

OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.

Receive News & Ratings for OncoSec Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply